Background:
A blend of creatine nitrate and creatinine has demonstrated promising
bioavailability; however, prior studies have not thoroughly examined its pharmacokinetics and
safety profiles, particularly its impact on kidney stress indicators, such as serum cystatin C.
Objective:
This study aimed to assess the effects of varying doses of creatine nitrate-creatinine intervention on pharmacokinetics and safety in healthy humans.
Methods:
Ten young adults (mean age 26.1 ± 5.0 years; 5 females) volunteered for this double-blind, crossover, randomized controlled trial. The participants were randomly assigned to receive either a low-dose creatine nitrate-creatinine mixture (CN-CRN-Low; 1.5 g of creatine nitrate
and 1.5 g of creatinine), a high-dose creatine nitrate-creatinine mixture (CN-CRN-High; 3 g of creatine nitrate and 3 g of creatinine), or 1.5 g of creatine nitrate (CONTROL) in both a single-dose
pharmacokinetics experiment, and a 14-day safety trial.
Results:
Both CN-CRN-Low and CN-CRN-High interventions displayed increased volume of distribution and total clearance compared to the CONTROL intervention (P < 0.05) in a single-dose
pharmacokinetics experiment. Additionally, the CN-CRN-High intervention showed significantly
higher creatine maximum serum concentrations compared to the other interventions (P < 0.05).
Serum cystatin C levels remained unchanged across all interventions (P = 0.65), with no participants experiencing abnormal cystatin C concentrations or major changes in other safety biomarkers.
Conclusion:
The present study demonstrates dose-specific utilization of creatine nitrate-creatinine
intervention, with the mixture induced no kidney damage. Further studies are needed to explore
the potential functional and performance benefits of creatine nitrate-creatinine supplementation in
diverse clinical and athletic cohorts.